Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Fong, Peter C., Boss, David S., Yap, Timothy A., Tutt, Andrew, Wu, Peijun, Mergui-Roelvink, Marja, Mortimer, Peter, Swaisland, Helen, Lau, Alan, O'Connor, Mark J., Ashworth, Alan, Carmichael, James, Kaye, Stan B., Schellens, Jan H.M., de Bono, Johann S.·2009·New England Journal of Medicine

DOI 10.1056/nejmoa0900212

Cited by (1,012)

Items 301–400 of 1,012

Rational Cancer Treatment Combinations: An Urgent Clinical Need
Julia Boshuizen, Daniel S. Peeper · 2020 · Molecular Cell
A genome-wide positioning systems network algorithm for in silico drug repurposing
Cheng, Feixiong, Lu, Weiqiang, Liu, Chuang, Fang, Jiansong, Hou, Yuan, Handy, Diane E., Wang, Ruisheng, Zhao, Yuzheng, Yang, Yi, Huang, Jin et al. · 2019 · Nature Communications
Ionizing radiation biomarkers for potential use in epidemiological studies
Eileen Pernot, Janet A. Hall, Sarah Baatout, Mohammed Abderrafi Benotmane, E. Blanchardon, Simon D Bouffler, Houssein El Saghire, Maria Gomolka, Anne Guertler, Mats Harms‐Ringdahl et al. · 2012 · Mutation Research/Reviews in Mutation Research
Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
Petra ter Brugge, Petra Kristel, Eline van der Burg, Ute Boon, Michiel de Maaker, Esther H. Lips, Lennart Mulder, Julian de Ruiter, Cátia Moutinho, Heidrun Gevensleben et al. · 2016 · JNCI Journal of the National Cancer Institute
The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers
Arindam Paul · 2014 · Frontiers in bioscience
RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination
Benjamin H. Lok, Alison C. Carley, B Tchang, Simon N. Powell · 2012 · Oncogene
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
Timothy Anthony Yap, Shahneen Kaur Sandhu, Craig P. Carden, Johann Sebastian De Bono · 2011 · CA A Cancer Journal for Clinicians
Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers
Åslaug Helland, Michael S. Anglesio, Joshy George, Prue A. Cowin, Cameron N. Johnstone, Colin M. House, Karen E. Sheppard, Dariush Etemadmoghadam, Nataliya Melnyk, Anil K. Rustgi et al. · 2011 · PLoS ONE
PARP inhibitor combination therapy
Amy Dréan, Christopher J. Lord, Alan Ashworth · 2016 · Critical Reviews in Oncology/Hematology
Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases
Nathan A. Berger, Valérie C. Besson, A. Hamid Boulares, Alexander Bürkle, Alberto Chiarugi, Robert S. B. Clark, Nicola J. Curtin, Salvatore Cuzzocrea, Ted M. Dawson, Valina Lynn Dawson et al. · 2017 · British Journal of Pharmacology
Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response
Han Zhu, June‐Wha Rhee, Paul P. Cheng, Sarah Waliany, Amy Chang, Ronald M. Witteles, Holden Terry Maecker, Mark M. Davis, Patricia Kim Phuong Nguyen, Sean M. Wu · 2020 · Current Cardiology Reports
Emerging targeted therapies in triple-negative breast cancer
John Paul Crown, Joyce O’Shaughnessy, Giuseppe Gullo · 2012 · Annals of Oncology
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
Tomasz Byrski, Rebecca Alexandra Dent, Paweł Blecharz, Małgorzata Foszczyńska‐Kłoda, Jacek Gronwald, Tomasz Huzarski, Cezary Cybulski, Elżbieta Marczyk, Robert M. Chrzan, Andrea F. Eisen et al. · 2012 · Breast Cancer Research
Basic Mechanisms of Therapeutic Resistance to Radiation and Chemotherapy in Lung Cancer
Henning Willers, Christopher G. Azzoli, Wil L. Santivasi, Fen Xia · 2013 · The Cancer Journal
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
Michalis Petropoulos, Angeliki Karamichali, Giacomo G. Rossetti, Alena Freudenmann, Luca Giacinto Iacovino, Vasilis S. Dionellis, Sotirios K. Sotiriou, Thanos D. Halazonetis · 2024 · Nature
Breast cancer stem cells: Biology and therapeutic implications
Ramesh Butti, Vinoth Prasanna Gunasekaran, Totakura V. S. Kumar, Pinaki Banerjee, Gopal C. Kundu · 2018 · The International Journal of Biochemistry & Cell Biology
Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib
Henk J. Broxterman, Kristy J. Gotink, Henk M.W. Verheul · 2009 · Drug Resistance Updates
Treatment of Advanced Prostate Cancer—A Review of Current Therapies and Future Promise
Semini Sumanasuriya, Johann Sebastian De Bono · 2017 · Cold Spring Harbor Perspectives in Medicine
Effects of BRCA1 - and BRCA2 -Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis
Qian Zhong, Hongling Peng, Xia Zhao, Lin Zhang, Wei‐Ting Hwang · 2014 · Clinical Cancer Research
DNA repair defects in cancer and therapeutic opportunities
Jessica L. Hopkins, Li Lan, Lee Zou · 2022 · Genes & Development
Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors
Poorval M. Joshi, Shari L. Sutor, Catherine J. Huntoon, Larry M. Karnitz · 2014 · Journal of Biological Chemistry
Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress
Monika Aggarwal, Joshua A. Sommers, Robert H. Shoemaker, Robert M. Brosh · 2011 · Proceedings of the National Academy of Sciences
DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1
Sarah A. Martin, Nuala McCabe, Michelle J Mullarkey, Robert Cummins, Darren J. Burgess, Yusaku Nakabeppu, Sugako Oka, Elaine Williamson Kay, Christopher J. Lord, Alan Ashworth · 2010 · Cancer Cell
Synthetic lethality: exploiting the addiction of cancer to DNA repair
Montaser F. Shaheen, Chris Allen, Jac A. Nickoloff, Robert Hromas · 2011 · Blood
Hereditary Breast and Ovarian Cancer
Alfons Meindl, Nina Caroline Ditsch, Karin Kast, Kerstin Rhiem, Rita Katharina Schmutzler · 2011 · Deutsches Ärzteblatt international
Identification of germline genetic mutations in patients with pancreatic cancer
Erin E. Salo‐Mullen, Eileen Mary O'Reilly, David Paul Kelsen, Asad M. Ashraf, Maeve Aine Lowery, Kenneth H. Yu, Diane L. Reidy‐Lagunes, Andrew S. Epstein, Anne Lincoln, Amethyst Saldia et al. · 2015 · Cancer
Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft
Joana M. Senra, Brian A. Telfer, Kim E. Cherry, Cian Michael McCrudden, David Graham Hirst, Mark J. O’Connor, Stephen R. Wedge, Ian James Stratford · 2011 · Molecular Cancer Therapeutics
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients
Marieke A. Vollebergh, Esther H. Lips, Petra M. Nederlof, Lodewyk F.A. Wessels, Marjanka K. Schmidt, Erik H. van Beers, Sten Cornelissen, M. Holtkamp, Femke E. Froklage, Elisabeth G.E. de Vries et al. · 2010 · Annals of Oncology
Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer
Elizabeth L. Christie, Sián Fereday, Kenneth Doig, Swetansu Pattnaik, Sarah‐Jane Dawson, David D.L. Bowtell · 2017 · Journal of Clinical Oncology
New therapeutic strategies to treat human cancers expressing mutant p53 proteins
Giovanni Blandino, Silvia Di Agostino · 2018 · Journal of Experimental & Clinical Cancer Research
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, Xuelei Ma, Shi H · 2022 · MedComm
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
Yvette Drew, Frank T. Zenke, Nicola J. Curtin · 2024 · Nature Reviews Drug Discovery
PALB2/FANCN: Recombining Cancer and Fanconi Anemia
Marc D. Tischkowitz, Bing Xia · 2010 · Cancer Research
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects
Roberta Ferraldeschi, Jonathan C. Welti, Jun Luo, Gerhardt Attard, Johann Sebastian De Bono · 2014 · Oncogene
Management of triple negative breast cancer
Catherine Angela Oakman, Giuseppe Viale, Angelo Di Leo · 2010 · The Breast
ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
Williamson, Chris T., Muzik, Huong, Turhan, Ali G., Zamò, Alberto, O'Connor, Mark J., Bebb, D. Gwyn, Lees-Miller, Susan P. · 2010 · Molecular Cancer Therapeutics
Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics
Goran B Jönsson, Johan Staaf, Johan Vallon‐Christersson, Markus Ringnér, Karolina Holm, Cecilia Hegardt, Haukur Gunnarsson, Rainer Fagerholm, Carina Strand, Bjarni Agnar Agnarsson et al. · 2010 · Breast Cancer Research
SPOP mutation leads to genomic instability in prostate cancer
Gunther Boysen, Christopher E. Barbieri, Davide Prandi, Mirjam Blattner, Sung‐Suk Chae, Arun Dahija, Srilakshmi Nataraj, Dennis Huang, Clarisse A. Marotz, Limei Xu et al. · 2015 · eLife
Olaparib: First Global Approval
Emma D. Deeks · 2015 · Drugs
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
Dedes, Konstantin J., Wilkerson, Paul M., Wetterskog, Daniel, Weigelt, Britta, Ashworth, Alan, Reis-Filho, Jorge S. · 2011 · Cell Cycle
Inhibition of Nicotinamide Phosphoribosyltransferase
Pittelli, Maria, Formentini, Laura, Faraco, Giuseppe, Lapucci, Andrea, Rapizzi, Elena, Cialdai, Francesca, Romano, Giovanni, Moneti, Gloriano, Moroni, Flavio, Chiarugi, Alberto · 2010 · Journal of Biological Chemistry
Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair
Emma Bolderson, Derek J. Richard, Bin‐Bing S. Zhou, Kum Kum Khanna · 2009 · Clinical Cancer Research
Emerging Targeted Therapies for Breast Cancer
Ricardo H. Álvarez, Vicente Valero, Gabriel N. Hortobágyi · 2010 · Journal of Clinical Oncology
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
Rebecca Alexandra Dent, Geoffrey John Lindeman, Mark J. Clemons, Hans P. M. W. Wildiers, Arlene Chan, Nicole McCarthy, Christian Fridolin Singer, Elizabeth Lowe, Claire L Watkins, James Carmichael · 2013 · Breast Cancer Research
Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses
Jung-Min Lee, John L. Hays, Christina M. Annunziata, Anne M. Noonan, Lori M. Minasian, Jo Anne Zujewski, Minshu Yu, Nicolas Gordon, Jiuping Jay Ji, Tristan M. Sissung et al. · 2014 · JNCI Journal of the National Cancer Institute
PARP Inhibition in Cancer: An Update on Clinical Development
Esha Sachdev, Roya Tabatabai, Varun Yadav Roy, B.J. Rimel, Monica M Mita · 2019 · Targeted Oncology
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer
Federico Rojo, Jetzabel García-Parra, Sandra Zazo, Ignasi Tusquets, Jaime Ferrer-Lozano, Sílvia Menéndez, Pîlar Eroles, Cristina Chamizo, Sònia Servitja, Natalia Ramírez-Merino et al. · 2011 · Annals of Oncology
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
Win Topatana, Sarun Juengpanich, Shijie Li, Jiasheng Cao, Jiahao Hu, Ji‐Young Lee, Kenneth Suliyanto, Diana Ma, Bin Zhang, Mingyu Chen et al. · 2020 · Journal of Hematology & Oncology
New strategies for targeting the hypoxic tumour microenvironment in breast cancer
Carol Ward, Simon P. Langdon, Peter Mullen, Adrian Llewellyn Harris, David James Harrison, Claudiu Trandafir Supuran, Ian H. Kunkler · 2012 · Cancer Treatment Reviews
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
Ahrum Min, Seock‐Ah Im, Debora Keunyoung Kim, Sang‐Hyun Song, Hee Jun Kim, Kyung-Hun Lee, Tae‐Yong Kim, Sae‐Won Han, Do‐Youn Oh, Tae‐You Kim et al. · 2015 · Breast Cancer Research
Targeting the DNA Repair Pathway in Ewing Sarcoma
Elizabeth A. Stewart, David Ross Goshorn, Cori L. Bradley, Lyra M. Griffiths, Claudia A. Benavente, Nathaniel R. Twarog, Gregory M. Miller, William V. Caufield, Burgess B. Freeman, Armita Bahrami et al. · 2014 · Cell Reports
PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors
Jordi Farrés, Laura Llacuna, Juan Martín‐Caballero, Carlos Manuel Martínez, Juan José Lozano, Coral Ampurdanés, Andres Joaquin Lopez-Contreras, Lourdes Florensa, Judith Navarro, Eleonora Ottina et al. · 2014 · Cell Death and Differentiation
Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity
Ethan S. Sokol, Dean C. Pavlick, Hossein Khiabanian, Garrett Michael Frampton, Jeffrey S. Ross, Jeffrey P. Gregg, Primo N. Lara, Steffi Oesterreich, Neeraj Agarwal, Andrea Necchi et al. · 2020 · JCO Precision Oncology
Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors
Christiane M. Robbins, Waibov A. Tembe, Angela S. Baker, Shripad A. Sinari, Tracy Y. Moses, Stephen M. Beckstrom‐Sternberg, James Beckstrom-Sternberg, Michael T. Barrett, James Patrick Long, Arul M. Chinnaiyan et al. · 2010 · Genome Research
Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors
Judith Balmañà, Nadine Tung, Steven Jay Isakoff, Begoña Graña, Patrick J. Ryan, Cristina Saura, Elizabeth Lowe, Paul Frewer, Eric P. Winer, Jose M Baselga et al. · 2014 · Annals of Oncology
Cisplatin Resistance Associated with PARP Hyperactivation
Michels, Judith, Vitale, Ilio, Galluzzi, Lorenzo, Adam, Julien, Olaussen, Ken André, Kepp, Oliver, Senovilla, Laura, Talhaoui, Ibtissam, Guegan, Justine, Enot, David Pierre et al. · 2013 · Cancer Research
MutationalPatterns: the one stop shop for the analysis of mutational processes
Freek Manders, Arianne M. Brandsma, Jurrian K. de Kanter, Mark Verheul, Rurika Oka, Markus J. van Roosmalen, Bastiaan R. Van der Roest, Arne van Hoeck, Edwin P. J. G. Cuppen, Ruben van Boxtel · 2022 · BMC Genomics
Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
Robert J. Cardnell, Ying Feng, Lixia Diao, You-Hong Fan, Fatemah Masrorpour, Jing Wang, Yuqiao Shen, Gordon Brent Mills, John Dorrance Minna, John Victor Heymach et al. · 2013 · Clinical Cancer Research
Treating Breast Cancer in the 21st Century: Emerging Biological Therapies
Gabriel Tinoco, Sean Warsch, Stefan Glück, Kiran Kumar Venkata Raja Avancha, Alberto J. Montero · 2013 · Journal of Cancer
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
Joyce F. Liu, Sara M. Tolaney, Michael J. Birrer, Gini F. Fleming, Mary Kathleen Buss, Suzanne Eleanor Dahlberg, Hang Lee, Christin Whalen, Karin Tyburski, Eric P. Winer et al. · 2013 · European Journal of Cancer
A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity
Stephen J. Pettitt, Farah L. Rehman, Ilirjana Bajrami, Rachel Brough, Fredrik Wållberg, Iwanka Kozarewa, Kerry Fenwick, Ioannis Assiotis, Lina Chen, James Campbell et al. · 2013 · PLoS ONE
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors
Anish Thomas, Christophe E. Redon, Linda C. Sciuto, Emerson Padiernos, Jiuping Jay Ji, Min-Jung Lee, Akira Yuno, Sunmin Lee, Yiping Zhang, Lan Thi-Ngoc Tran et al. · 2017 · Journal of Clinical Oncology
BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)- Ribose Polymerase Inhibitors
Jürgen Veeck, Santiago Ropero, Fernando Setién, Eva González‐Suárez, Ana Osório, Javier J. Benitez, James Gordon Herman, Manel Esteller · 2010 · Journal of Clinical Oncology
Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
Xuesong Liu, Yan Shi, David Maag, Joann P. Palma, Melanie J. Schroeder Patterson, Paul A. Ellis, Bruce W. Surber, Damien B. Ready, Niru B. Soni, Uri S. Ladror et al. · 2011 · Clinical Cancer Research
Recent developments in the use of γ -H2AX as a quantitative DNA double-strand break biomarker
Christophe E. Redon, Asako Nakamura, Olga A. Martin, Palak R. Parekh, Urbain Weyemi, William M. Bonner · 2011 · Aging
miR-9 Regulation of BRCA1 and Ovarian Cancer Sensitivity to Cisplatin and PARP Inhibition
Chaoyang Sun, Na Li, Zongyuan Yang, Bo Zhou, Yang He, Danhui Weng, Yong Fang, Peng Wu, Pingbo Chen, Xiaokui Yang et al. · 2013 · JNCI Journal of the National Cancer Institute
Biomarker-Driven Early Clinical Trials in Oncology
Daniel S.W. Tan, GEORGE V. THOMAS, Michelle Dawn Garrett, Udai Banerji, Johann Sebastian De Bono, Stan B. Kaye, Paul Workman · 2009 · The Cancer Journal
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Dana Jurkovičová, Christiana Michael Neophytou, Ana Čipak Gašparović, Ana Cristina Gonçalves · 2022 · International Journal of Molecular Sciences
The role of BRCA1 and BRCA2 in prostate cancer
Elena Castro, Rosalind A. Eeles · 2012 · Asian Journal of Andrology
Targeting triple-negative breast cancer: optimising therapeutic outcomes
Karen A. Gelmon, Rebecca Alexandra Dent, John Robert Mackey, Kara E. Laing, Deanna McLeod, Sunil Verma · 2012 · Annals of Oncology
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside
Anita Ahmed Turk, Kari Braun Wisinski · 2018 · Cancer
Clonal evolution in hematological malignancies and therapeutic implications
Dan Avi Landau, Scott L. Carter, Gad A. Getz, Catherine J. Wu · 2013 · Leukemia
Triple-Negative Breast Carcinoma
Robert Schmadeka, Bryan E. Harmon, Meenakshi Singh · 2014 · American Journal of Clinical Pathology
Germline Brca2 Heterozygosity Promotes Kras -Driven Carcinogenesis in a Murine Model of Familial Pancreatic Cancer
Ferdinandos Skoulidis, Liam D. Cassidy, Venkat Pisupati, Jon Gunnlaugur Jonasson, Hörður Bjarnason, Jorunn Erla Eyfjord, Florian A. Karreth, Michael Lim, Lorraine M. Barber, Susan A. Clatworthy et al. · 2010 · Cancer Cell
Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors
Maria Teresa Esposito, Lu Zhao, Tsz Kan Fung, Jayant K. Rane, Amanda Wilson, Nadine Martin, Jesús Gil, Anskar Y.H. Leung, Alan Ashworth, Chi Wai Eric So · 2015 · Nature Medicine
Biosensors as diagnostic tools in clinical applications
Catarina Lino, Sara Barrias, Raquel Chaves, Filomena Adega, Paula Martins‐Lopes, José Ramiro Fernandes · 2022 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
The Zn3 Domain of Human Poly(ADP-ribose) Polymerase-1 (PARP-1) Functions in Both DNA-dependent Poly(ADP-ribose) Synthesis Activity and Chromatin Compaction
Marie-France Langelier, Donald D. Ruhl, Jamie L. Planck, W. Lee Kraus, John M. Pascal · 2010 · Journal of Biological Chemistry
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
Markus K. Muellner, Iris Z. Uras, Bianca V. Gapp, Claudia Kerzendorfer, Michal Šmída, Hannelore Lechtermann, Nils Craig-Mueller, Jacques Colinge, Gerhard Duernberger, Sebastian M. B. Nijman · 2011 · Nature Chemical Biology
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion
Jerry F. Tien, Alborz Mazloomian, Siwei Cheng, Christopher S. Hughes, Christalle C. T. Chow, Leanna T. Canapi, Arusha Oloumi, Genny Trigo‐Gonzalez, Ali Bashashati, James Xu et al. · 2017 · Nucleic Acids Research
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
Dae-Seok Kim, Cristel V. Camacho, W. Lee Kraus · 2021 · Experimental & Molecular Medicine
Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer—Response
Robert J. Cardnell, Lauren A. Byers · 2014 · Clinical Cancer Research
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
Lenka Oplustilova, Kamila Wolanin, Martin Mistrík, Gabriela Kořínková, Dana Šimková, Jan Bouchal, René Lenobel, Jiřina Bártková, Alan Lau, Mark J. O’Connor et al. · 2012 · Cell Cycle
A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
Arun Rajan, Corey Allan Carter, Ronan Joseph Kelly, Martin E Gutierrez, Shivaani Kummar, Eva M. Szabo, Mary Ann Yancey, Jiuping Jay Ji, Baskar M. Mannargudi, Sukyung Woo et al. · 2012 · Clinical Cancer Research
Detection and Repair of Ionizing Radiation-Induced DNA Double Strand Breaks: New Developments in Nonhomologous End Joining
Chen Wang, Susan P. Lees‐Miller · 2013 · International Journal of Radiation Oncology*Biology*Physics
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer
Yajing Liu, Monika Leigh Burness, Rachel Martin-Trevino, Joey Guy, Shoumin Bai, Ramdane A Harouaka, Michael D. Brooks, Shang Li, Alexandra Lucienne Fox, Tahra Kaur Luther et al. · 2016 · Clinical Cancer Research
Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
Peter Bouwman, Jos Jonkers · 2013 · Clinical Cancer Research
Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment
Kishan A.T. Naipal, Nicole S. Verkaik, Najim Ameziane, Carolien H. M. van Deurzen, Petra ter Brugge, Matty Meijers, Anieta M. Sieuwerts, John W.M. Martens, Mark J. O’Connor, Harry Vrieling et al. · 2014 · Clinical Cancer Research
PARP Inhibitor Treatment in Ovarian and Breast Cancer
Marcie K. Weil, Alice P. Chen · 2011 · Current Problems in Cancer
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
Yvette Drew, Jonathan Andrew Ledermann, Geoff D. Hall, Daniel William Rea, Rosalind Margaret Glasspool, Martin Highley, Gordon C. Jayson, Julieann Sludden, James Murray, David Jamieson et al. · 2016 · British Journal of Cancer
BRCA mutations in the management of breast cancer: the state of the art
Steven Alexander Narod · 2010 · Nature Reviews Clinical Oncology
Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies
Daniel Joseph Toft, Vincent L. Cryns · 2010 · Molecular Endocrinology
Therapeutic Targeting of the DNA Mismatch Repair Pathway
Sarah A. Martin, Christopher J. Lord, Alan Ashworth · 2010 · Clinical Cancer Research
First international consensus guidelines for breast cancer in young women (BCY1)
Ann H. Partridge, Olivia Pagani, Omalkhair A. M. Abulkhair, Stefan Paul Aebi, Frédéric C. Amant, Hatem A. Azim, Alberto Costa, Suzette Delaloge, Gloria Freilich, Oreste Gentilini et al. · 2014 · The Breast
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
Jens Samol, Malcolm Ranson, Edwina N. Scott, Euan Macpherson, James Carmichael, Anne Thomas, James Cassidy · 2011 · Investigational New Drugs
Management of breast cancer with targeted agents: importance of heterogenicity
Serena Di Cosimo, Jose M Baselga · 2010 · Nature Reviews Clinical Oncology
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety
Ursula A. Matulonis, Richard T. Penson, S. M. Domchek, Bella Kaufman, Ronnie Shapira‐Frommer, M. William Audeh, Stanley B. Kaye, L. Rhoda Molife, Karen A. Gelmon, Jane D. Robertson et al. · 2016 · Annals of Oncology
Drugging the Cancers Addicted to DNA Repair
Jac A. Nickoloff, Dennie V. Jones, Suk‐Hee Lee, Elizabeth A. Williamson, Robert Hromas · 2017 · JNCI Journal of the National Cancer Institute
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
George, Angela, Kaye, Stan, Banerjee, Susana · 2017 · Nature Reviews Clinical Oncology
Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
Kaplan, Alanna R., Gueble, Susan E., Liu, Yanfeng, Oeck, Sebastian, Kim, Hoon, Yun, Zhong, Glazer, Peter M. · 2019 · Science Translational Medicine
Preclinical development of molecular-targeted agents for cancer
Alberto Ocaña, Atanasio Pandiella, Lillian L. Siu, Ian F. Tannock · 2010 · Nature Reviews Clinical Oncology